Consistent with this view, multiple clinical trials with second-generation ADCs targeting FOLR1 in ovarian cancer patients are currently ongoing (Sutro Biopharma, Inc., San Francisco, CA, USA) [89]. This evidence concerns the gene FOLR1 and ovarian carcinoma.